Adding zilebesiran to a thiazide diuretic or calcium channel blocker may lead to further blood pressure reduction in patients with uncontrolled hypertension. Zilebesiran added to hypertension ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

The trial will initially involve healthy obese people receiving single and multiple escalating doses of the therapy.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Arrowhead Pharmaceuticals, Inc. today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic being ...

After providing an overview of the various classes of nonlinear interference noise (NLIN) and digital signal processing approaches for their mitigation, we consider the two practically most relevant ...

This triggered the development of RNA interference as a tool, and with it came a myriad of investigations into the function of genes. For researchers working with prokaryotes it is now 1998.

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA ...

Silexion Therapeutics Corp. has released preclinical data demonstrating the efficacy of its next-generation RNA interference ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; ...